Health Care

More

• Keryx shares keep climbing on drug trial results

  Shares of Keryx Biopharmaceuticals Inc. extended its gains Tuesday, a day after the drug developer said its potential kidney disease drug, Zerenex, performed much better than a placebo in a late-stage clinical trial.

• Roche CEO: Emerging Markets Key to Momentum

  

  Emerging markets, and in particular, Latin America will be the drivers for continued growth, Swiss drug maker Roche told CNBC, even as the company faces price pressures elsewhere.

• Eli Lilly Loses to Generics, but Beats Estimates

  

  Eli Lilly said fourth-quarter earnings fell as competition from generic drugs, particularly for Zyprexa, drove revenue lower.

• UPDATE 1-Lilly loses ground in fourth quarter to generics

  Jan 29- Eli Lilly and Co said on Tuesday that fourth-quarter earnings fell as competition from generic drugs, particularly for its top-selling schizophrenia drug Zyprexa, drove revenue lower. The U.S. drugmaker earned $827 million, or 74 cents per share, compared with $858 million, or 77 cents per share, a year earlier.

• Lilly fourth-quarter profit fall as generics hurt sales

  Jan 29- Eli Lilly and Co said on Tuesday that fourth-quarter earnings had fallen as competition from generic drugs drove revenue lower. The U.S. drugmaker said it had earned $827 million, or 74 cents per share, compared with $858 million, or 77 cents per share, a year earlier.

• Opko Health CEO on Cytochromas Acquisition 

  

  Opko Health chairman and CEO Dr. Phillip Frost, offers insight on his company's acquisition of Cytochromas, its partnerships with companies like Bristol-Meyers Squibb, and where the company is headed this year.

• Furiex jumps after diabetes drug approval

  NEW YORK-- Shares of Furiex Pharmaceuticals Inc. surged Monday after regulators approved three new diabetes drugs that Japanese drugmaker Takeda developed with help from Furiex. THE SPARK: On Friday, Takeda said the Food and Drug Administration approved the type 2 diabetes drug Nesina and the combination drugs Oseni and Kazano.

• FDA accepts application for new Sanofi MS drug

  NEW YORK-- French drugmaker Sanofi said Monday that the Food and Drug Administration will review its experimental multiple sclerosis treatment Lemtrada.

• Keryx shares soar on kidney drug results

  NEW YORK-- Shares of Keryx Biopharmaceuticals Inc. soared Monday after the drug developer said its potential kidney disease drug, Zerenex, performed much better than a placebo in a late-stage clinical trial.

• UPDATE 2-Medical isotope maker Nordion explores alternatives

  Jan 28- Canada's Nordion Inc, a major provider of medical isotopes, said on Monday it has hired advisers to examine options for its future, sending its shares sharply higher. Nordion suspended its dividend in September after an arbitration panel rejected its claim for damages from its main supplier, state-owned Atomic Energy of Canada Ltd..

• Market Winners & Losers: Travel, Health Care & More 

  

  CNBC's Seema Mody reports on some of the week's biggest winning and losing stocks, saying health care was one of the better performing sectors for the week.

• FDA approves 3 new diabetes drugs from Takeda

  WASHINGTON-- The Food and Drug Administration on Friday approved three new formulations of a Takeda Pharmaceuticals Co. Ltd. diabetes drug designed to help patients control their blood sugar. The FDA approved the drug in stand-alone form under the brand-name Nesina.

• Earnings Preview: Pfizer to focus on new drug OKs

  Pfizer Inc. will tout a surge of new drug approvals, and an acquisition that's brought the world's biggest drugmaker another new medicine, when it reports fourth-quarter results Tuesday morning.

• FDA head and company CEOs cheer bumper haul of new drugs

  *Approvals in past 2 years "cause for optimism"- FDA head. DAVOS, Switzerland, Jan 25- Pharmaceutical industry productivity is improving as a more targeted approach to drug development yields dividends and regulators offer speedier decisions on medicines that make a real difference to patients.

• UPDATE 1-FDA OKs Merck OTC version of overactive bladder drug

  Jan 25- U.S. health regulators approved Merck& Co's nonprescription version of Oxytrol to treat overactive bladder in women ages 18 and older, the agency said on Friday. Oxytrol for Women is a patch that contains oxybutynin, a medicine that helps relax the bladder muscle, and is designed to be applied to the skin every four days, the FDA said.

• Cancer drug developer ImmunoGen takes bigger loss

  WALTHAM, Mass.-- Drug developer ImmunoGen Inc. said Friday its fiscal second quarter nearly doubled, as it continued developing treatments for cancer. The Food and Drug Administration is scheduled to make a decision on T-DM1 by Feb. 26. The companies have asked the FDA and European regulators to approve T-DM1 as a treatment for breast cancer.

• Actavis predicts 2013 profit growth short of St.

  PARSIPPANY, N.J.-- Generic drug developer Actavis Inc., formerly named Watson Pharmaceuticals, predicted profit growth for 2013 that was short of Wall Street's expectations. The Parsippany, N.J., company changed its name to Actavis after buying Swiss drugmaker Actavis Group for about $5.6 billion in October.

• Actavis, formerly Watson, sees 2013 profit growth

  Jan 25- Actavis Inc, the generic drugmaker previously known as Watson Pharmaceuticals, said on Friday that it expected earnings to rise at least 30 percent in 2013 as it expands globally, but its outlook still came in short of analysts' expectations.

• Rep. Cantor: You Will Not See Higher Taxes 

  

  Rep. Eric Cantor (R-VA) discusses the debt ceiling, tax reform and how the U.S. can balance its budget, with CNBC's Maria Bartiromo.

• Watson Pharma changes name to Actavis Inc.

  PARSIPPANY, N.J.-- Watson Pharmaceuticals Inc. said Thursday it has changed its name to Actavis Inc. following its purchase of the Swiss drugmaker in October. As part of the change, the company's New York Stock Exchange ticker symbol switched to "ACT" from "WPI." Watson agreed to buy Actavis Group in April for about $5.6 billion.